Can Wegovy Affect Your Liver — and What Does the Evidence Actually Say?

Step 1: Understanding what semaglutide does to liver fat in the first place

A widespread assumption is that weight-loss medicines only work on appetite. Semaglutide does reduce hunger and slow gastric emptying, but its effects reach further than that. Excess fat stored in and around the liver is closely linked to metabolic conditions such as type 2 diabetes, insulin resistance and obesity, and as body weight falls during treatment, liver fat tends to fall with it.

Research has consistently shown reductions in intrahepatic lipid content among people taking semaglutide, alongside improvements in alanine aminotransferase (ALT), an enzyme that rises when liver cells are under stress. A relevant reference point is the STEP 1 trial, published in the New England Journal of Medicine, which recorded an average body-weight reduction of around 15% at 68 weeks with semaglutide 2.4mg alongside lifestyle changes. Sustained weight loss of that scale reliably improves fatty liver in most people. The mechanism is not fully understood at a molecular level, but it appears to involve both the indirect benefit of weight reduction and a more direct action on liver metabolism.

It is worth reading more about how Wegovy interacts with the liver across different doses and conditions if this is your main concern, because the picture varies depending on baseline liver health.

Step 2: The MASH approval, what it means and what it does not mean

On 3 July 2026, the MHRA granted Wegovy conditional approval to treat MASH in adults who already have moderate-to-advanced liver fibrosis. This is a genuinely significant development. MASH (metabolic dysfunction-associated steatohepatitis) is a progressive form of fatty liver disease that can lead to cirrhosis and liver failure if untreated. The MHRA announcement confirmed this conditional approval and described the evidence supporting it.

What this does not mean is that everyone with a liver complaint is automatically a candidate for Wegovy, or that a prescription for weight management automatically covers MASH treatment. These are distinct licensed indications. If you have been diagnosed with MASH or significant liver fibrosis, the right route is a conversation with your hepatologist or gastroenterologist, who can assess whether Wegovy is appropriate alongside any existing management plan. A private weight-management consultation can still be a useful starting point to understand your options (you can start a free consultation with a GPhC-registered prescriber here) but a specialist should be involved in decisions that touch active liver disease.

Step 3: Situations where the liver question needs more care

Most people who take Wegovy for weight management have no significant liver problems and will not experience any meaningful adverse liver effects. Serious hepatotoxicity is not listed as a common or expected side effect in the Wegovy SmPC or on the NHS medicines page for semaglutide. That said, three groups deserve extra thought.

First, people with established cirrhosis or severe liver impairment. The SmPC does not recommend Wegovy in those with severe hepatic impairment, because the drug has not been adequately studied in this population. Second, people taking medicines that are themselves hepatotoxic, the combination requires clinical review. Third, people who notice symptoms such as persistent fatigue, yellowing of the skin or eyes, dark urine, or upper-right abdominal discomfort while on Wegovy; these are not typical Wegovy side effects and warrant prompt medical assessment, not a wait-and-see approach.

For a broader read on how semaglutide can affect your liver in different contexts, the semaglutide and liver overview covers the evidence across both weight-management and diabetes indications.

Step 4: What to tell your prescriber, and who to involve

If you have a history of liver disease, abnormal liver function tests, or you are being monitored by a hepatologist, mention this at the start of your consultation. It does not automatically rule you out. Mild non-alcoholic fatty liver disease is, paradoxically, one of the conditions that Wegovy may help, but the right dose, monitoring plan and any interactions with existing treatment need a qualified clinician's eyes, not a self-assessment.

For most people asking whether Wegovy can affect the liver, the short answer is that it most commonly affects it positively, in line with the weight reduction it produces. The concern about liver harm is understandable (it is a question our prescribers hear regularly) but it rarely reflects what the evidence shows at typical doses in otherwise healthy adults. A closer look at the specific mechanisms behind that benefit may help if you want to read further before your consultation.

For anything related to heart health alongside liver concerns, the cardiovascular picture for Wegovy is covered separately and is worth reviewing if you have overlapping conditions. Our clinical team, led by our GPhC-registered independent prescriber, reviews every consultation personally before any treatment is approved. If you are also considering Wegovy while pregnant or planning a pregnancy, our guidance on Wegovy and pregnancy explains what the current evidence and prescribing advice say.